Patents by Inventor Jonathan D. Low
Jonathan D. Low has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240050430Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: June 23, 2023Publication date: February 15, 2024Inventors: John Gordon ALLEN, Jennifer Rebecca ALLEN, Ana Elena MINATTI, Qiufen XUE, Ryan Paul WURZ, Christopher M. TEGLEY, Alexander J. PICKRELL, Thomas T. NGUYEN, Vu Van MA, Patricia LOPEZ, Longbin LIU, David John KOPECKY, Michael J. FROHN, Ning CHEN, Jian Jeffrey CHEN, Aaron C. SIEGMUND, Albert AMEGADZIE, Nuria A. TAMAYO, Shon BOOKER, Clifford GOODMAN, Mary WALTON, Nobuko NISHIMURA, Youngsook SHIN, Jonathan D. LOW, Victor J. CEE, Anthony B. REED, Hui-Ling WANG, Brian Alan LANMAN
-
Patent number: 11766436Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: June 30, 2021Date of Patent: September 26, 2023Assignee: Amgen Inc.Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman
-
Publication number: 20220395504Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: June 30, 2021Publication date: December 15, 2022Inventors: John Gordon ALLEN, Jennifer Rebecca ALLEN, Ana Elena MINATTI, Qiufen XUE, Ryan Paul WURZ, Christopher M. TEGLEY, Alexander J. PICKRELL, Thomas T. NGUYEN, Vu Van MA, Patricia LOPEZ, Longbin LIU, David John KOPECKY, Michael J. FROHN, Ning CHEN, Jian Jeffrey CHEN, Aaron C. SIEGMUND, Albert AMEGADZIE, Nuria A. TAMAYO, Shon BOOKER, Clifford GOODMAN, Mary WALTON, Nobuko NISHIMURA, Youngsook SHIN, Jonathan D. LOW, Victor J. CEE, Anthony B. REED, Hui-Ling WANG, Brian Alan LANMAN
-
Publication number: 20220213101Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: March 10, 2022Publication date: July 7, 2022Inventors: Brian Alan LANMAN, Shon BOOKER, Clifford GOODMAN, Anthony B. REED, Jonathan D. LOW, Hui-Ling WANG, Ning CHEN, Ana Elena MINATTI, Ryan WURZ, Victor J. CEE
-
Publication number: 20220175782Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: January 19, 2022Publication date: June 9, 2022Inventors: John Gordon ALLEN, Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon BOOKER, Jennifer Rebecca ALLEN, Margaret CHU-MOYER, Albert AMEGADZIE, Ning CHEN, Clifford GOODMAN, Jonathan D. LOW, Vu Van MA, Ana Elena MINATTI, Nobuko NISHIMURA, Alexander J. PICKRELL, Hui-Ling WANG, Youngsook SHIN, Aaron C. SIEGMUND, Kevin C. YANG, Nuria A. TAMAYO, Mary WALTON, Qiufen XUE
-
Publication number: 20220169611Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.Type: ApplicationFiled: February 15, 2022Publication date: June 2, 2022Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Dequette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua Ma, Lawrence R. McGee, Josel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
-
Patent number: 11306087Abstract: Provided herein are methods of using KRAS G12C inhibitors. These methods of using the inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: March 12, 2020Date of Patent: April 19, 2022Assignee: AMGEN INC.Inventors: Brian Alan Lanman, Shon Booker, Clifford Goodman, Anthony B. Reed, Jonathan D. Low, Hui-Ling Wang, Ning Chen, Ana Elena Minatti, Ryan Wurz, Victor J. Cee
-
Patent number: 11285156Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: June 11, 2019Date of Patent: March 29, 2022Assignee: AMGEN INC.Inventors: John Gordon Allen, Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Jennifer Rebecca Allen, Margaret Chu-Moyer, Albert Amegadzie, Ning Chen, Clifford Goodman, Jonathan D. Low, Vu Van Ma, Ana Elena Minatti, Nobuko Nishimura, Alexander J. Pickrell, Hui-Ling Wang, Youngsook Shin, Aaron C. Siegmund, Kevin C. Yang, Nuria A. Tamayo, Mary Walton, Qiufen Xue
-
Patent number: 11279712Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: August 27, 2018Date of Patent: March 22, 2022Assignee: AMGEN INC.Inventors: Sean P. Brown, Yunxiao Li, Paul E. Harrington, Brian Alan Lanman, Jonathan D. Low, Ana Elena Minatti, Vu Van Ma, Kexue Li
-
Patent number: 11224601Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: September 23, 2020Date of Patent: January 18, 2022Assignee: AMGEN INC.Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
-
Patent number: 11090304Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: May 3, 2019Date of Patent: August 17, 2021Assignee: Amgen Inc.Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman
-
Publication number: 20210179560Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.Type: ApplicationFiled: August 3, 2020Publication date: June 17, 2021Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
-
Publication number: 20210171529Abstract: The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula 1: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.Type: ApplicationFiled: November 24, 2020Publication date: June 10, 2021Inventors: Jennifer R. ALLEN, Albert AMEGADZIE, Matthew P. BOURBEAU, Ning CHEN, Clifford GOODMAN, Giulia LATTANZI, Iain LINGARD, Qingyian LIU, Jonathan D. LOW, Vu Van MA, Ana E. MINATTI, Alfonso POZZAN, Corey REEVES, Aaron C. SIEGMUND, Sabrina TASSINI, Federica TONELLI, Mary WALTON
-
Patent number: 10889581Abstract: The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, R1, R2, R2?, R3, R4, and R5 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A? plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.Type: GrantFiled: December 13, 2017Date of Patent: January 12, 2021Assignee: Amgen Inc.Inventors: Jennifer R. Allen, Albert Amegadzie, Matthew P. Bourbeau, Jian J. Chen, Michael J. Frohn, Paul E. Harrington, Jonathan D. Low, Vu V. Ma, Thomas T. Nguyen, Alexander Pickrell, Corey Reeves
-
Patent number: 10821115Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: February 6, 2020Date of Patent: November 3, 2020Assignee: AMGEN INC.Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
-
Publication number: 20200247821Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: ApplicationFiled: August 27, 2018Publication date: August 6, 2020Applicant: AMGEN INC.Inventors: Sean P. BROWN, Yunxiao LI, Paul E. HARRINGTON, Brian Alan LANMAN, Jonathan D. LOW, Ana Elena MINATTI, Vu Van MA, Kexue LI
-
Publication number: 20200231585Abstract: The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I) wherein variables A, R1, R2, R2?, R3, R4, and R5 of Formula (I) are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A? plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.Type: ApplicationFiled: December 13, 2017Publication date: July 23, 2020Applicant: AMGEN INC.Inventors: Jennifer R. ALLEN, Albert AMEGADZIE, Matthew P. BOURBEAU, Jian J. CHEN, Michael J. FROHN, Paul E. HARRINGTON, Jonathan D. LOW, Vu V. MA, Thomas T. NGUYEN, Alexander PICKRELL, Corey REEVES
-
Publication number: 20200207766Abstract: Provided herein are methods of using KRAS G12C inhibitors. These methods of using the inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: March 12, 2020Publication date: July 2, 2020Inventors: Brian Alan LANMAN, Shon BOOKER, Clifford GOODMAN, Anthony B. REED, Jonathan D. LOW, Hui-Ling WANG, Ning CHEN, Ana Elena MINATTI, Ryan WURZ, Victor J. CEE
-
Publication number: 20200171043Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: ApplicationFiled: February 6, 2020Publication date: June 4, 2020Applicant: AMGEN INC.Inventors: Paul E. HARRINGTON, Kate ASHTON, Sean P. BROWN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Yunxiao LI, Jonathan D. LOW, Ana Elena MINATTI, Alexander J. PICKRELL, Markian M. STEC, Joshua TAYGERLY
-
Patent number: 10640504Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: September 7, 2018Date of Patent: May 5, 2020Assignee: Amgen Inc.Inventors: Brian Alan Lanman, Shon Booker, Clifford Goodman, Anthony B. Reed, Jonathan D. Low, Hui-Ling Wang, Ning Chen, Ana Elena Minatti, Ryan Wurz, Victor J. Cee